Literature DB >> 22858082

Effect of colchicine on myocardial injury induced by Trypanosoma cruzi in experimental Chagas disease.

Fábio Fernandes1, Felix José Alvarez Ramires, Barbara Maria Ianni, Vera Maria Cury Salemi, Adriana Morgan Oliveira, Fernanda Gallinaro Pessoa, Mauro Canzian, Charles Mady.   

Abstract

BACKGROUND: The hallmark of Chagas disease (CD) is multifocal myocarditis and extensive fibrosis. We investigated the potential effect of colchicine on myocardial remodeling in experimental CD. METHODS AND
RESULTS: One hundred Syrian hamsters were randomly divided into noninfected untreated control (CG), noninfected control treated with colchicine (COLG 0.4 mg kg(-1) d(-1) by gavage), infected (IG), and infected treated with colchicine (ICOLG, 0.4 mg kg(-1) d(-1)) groups. The interstitial collagen volume fraction (ICVF) was evaluated by videomorphometry with picrosirius red staining. The gelatinolytic activities of matrix metalloproteinase (MMP) 2 were examined with the use of zymography. Myocarditis was described according to the Dallas criteria. Statistical comparisons were performed with parametric analysis of variance and Tukey test. ICVF (%) accumulation was attenuated in infected colchicine-treated animals in the left (CG 0.81 ± 0.13, COLG 0.85 ± 0.13, IG: 1.35 ± 0.31,* ICOLG 1.06 ± 0.19; *P < .05 compared with ICOLG) and right ventricles (CG 1.4 ± 0.36, COLG 1.26 ± 0.14, IG 1.97 ± 0.058,* ICOLG: 1.52 ± 0.23; *P < .05 compared with ICOLG). A significant increase in MMP-2 enzymatic activity (UA) was observed in ICOLG (17,432.8*) compared with GC (3731.6), COLG (2,792.6), and IG (4,286.3; *P < .001). In IG, 66% of animals had myocarditis compared with only 49% in ICOLG.
CONCLUSIONS: Colchicine had a protective effect on myocardium, indicated by decreased interstitial myocardial fibrosis, increased intensity of MMP-2, and attenuated myocardial inflammation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22858082     DOI: 10.1016/j.cardfail.2012.06.419

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  10 in total

1.  Colchicine treatment reversibly blocks cytokinesis but not mitosis in Trypanosoma cruzi epimastigotes.

Authors:  Mariana Potenza; María Teresa Tellez-Iñón
Journal:  Parasitol Res       Date:  2014-11-20       Impact factor: 2.289

Review 2.  Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review.

Authors:  Christodoulos Papadopoulos; Dimitrios Patoulias; Eleftherios Teperikidis; Dimitrios Mouselimis; Anastasios Tsarouchas; Maria Toumpourleka; Aristi Boulmpou; Constantinos Bakogiannis; Michael Doumas; Vassilios P Vassilikos
Journal:  SN Compr Clin Med       Date:  2020-08-04

Review 3.  Colchicine in Pericardial Disease: from the Underlying Biology and Clinical Benefits to the Drug-Drug Interactions in Cardiovascular Medicine.

Authors:  Aldo L Schenone; Venu Menon
Journal:  Curr Cardiol Rep       Date:  2018-06-14       Impact factor: 2.931

4.  Colchicine modulates calcium homeostasis and electrical property of HL-1 cells.

Authors:  Yen-Yu Lu; Yao-Chang Chen; Yu-Hsun Kao; Yung-Kuo Lin; Yung-Hsin Yeh; Shih-Ann Chen; Yi-Jen Chen
Journal:  J Cell Mol Med       Date:  2016-02-29       Impact factor: 5.310

Review 5.  Introducing variability in targeting the microtubules: Review of current mechanisms and future directions in colchicine therapy.

Authors:  Esther Forkosh; Ariel Kenig; Yaron Ilan
Journal:  Pharmacol Res Perspect       Date:  2020-08

Review 6.  Trypanosomatid-Caused Conditions: State of the Art of Therapeutics and Potential Applications of Lipid-Based Nanocarriers.

Authors:  Giuliana Muraca; Ignacio Rivero Berti; María L Sbaraglini; Wagner J Fávaro; Nelson Durán; Guillermo R Castro; Alan Talevi
Journal:  Front Chem       Date:  2020-11-26       Impact factor: 5.221

7.  Matrix Metalloproteinase 2 and 9 Enzymatic Activities are Selectively Increased in the Myocardium of Chronic Chagas Disease Cardiomyopathy Patients: Role of TIMPs.

Authors:  Monique Andrade Baron; Ludmila Rodrigues Pinto Ferreira; Priscila Camillo Teixeira; Ana Iochabel Soares Moretti; Ronaldo Honorato Barros Santos; Amanda Farage Frade; Andréia Kuramoto; Victor Debbas; Luiz Alberto Benvenuti; Fabio Antônio Gaiotto; Fernando Bacal; Pablo Pomerantzeff; Christophe Chevillard; Jorge Kalil; Edecio Cunha-Neto
Journal:  Front Cell Infect Microbiol       Date:  2022-03-17       Impact factor: 5.293

8.  Air Pollution's Impact on Cardiac Remodeling in an Experimental Model of Chagas Cardiomyopathy.

Authors:  Keila Cardoso Barbosa Fonseca; Fernanda Gallinaro Pessoa; Orlando do Nascimento Ribeiro; Viviane Tiemi Hotta; Barbara Maria Ianni; Fabio Fernandes; Dolores Helena Rodriguez Ferreira Rivero; Paulo Hilário Nascimento Saldiva; Charles Mady; Felix José Alvarez Ramires
Journal:  Front Cell Infect Microbiol       Date:  2022-07-19       Impact factor: 6.073

9.  What's Old is New Again - A Review of the Current Evidence of Colchicine in Cardiovascular Medicine.

Authors:  Bryan P Yan; Guang-Ming Tan
Journal:  Curr Cardiol Rev       Date:  2017

10.  Evaluation of low-dose colchicine in patients with cardiopulmonary bypass: study protocol for a randomised controlled trial.

Authors:  He Zhang; Xikun Han; Tuo Pan; Hai-Tao Zhang; Kai Zhong; Ze-Shi Li; Xinyi Jiang; Jun Pan; Dong-Jin Wang
Journal:  BMJ Open       Date:  2022-02-01       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.